Enterprise Value
2.649B
Cash
933.5M
Avg Qtr Burn
-90.7M
Short % of Float
7.63%
Insider Ownership
5.61%
Institutional Own.
87.91%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NTLA-2002 (KLKB1 Inhibitor) Details Hereditary angioedema , Rare diseases, Rare genetic disease | Phase 1/2 Data readout | |
NTLA-2001 (CRISPR/Cas9) Details Transthyretin amyloidosis | Phase 1 Data readout | |
NTLA-5001 Details Acute myeloid leukemia | Failed Discontinued | |
OTQ923 / HIX763 (Hematopoietic Stem Cells (HSC)) Details Sickle cell disease | Failed Discontinued |